NOTA Stock Price and Chart — SWB:NOTA

Key facts today

On November 1, 2025, Novartis launched a direct-to-patient platform in the U.S. for Cosentyx, offering a 55% discount for cash-paying patients. Expansion plans include more products.

Novartis has initiated a tender offer to acquire all outstanding shares of Tourmaline Bio, Inc. at a price of $48 per share in cash, with the offer set to expire on October 27, 2025, unless extended.

Novartis partners with dHealth Intelligence to develop an AI platform that consolidates medical data and offers private consultations, tackling fragmented medical records.

Analyze the impact Analyze the impact

About Novartis AG

Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment includes researching, distributing and selling patented pharmaceuticals. The Sandoz segment focuses on marketing finished dosage form medicines and intermediary products including active pharmaceutical ingredients. The Corporate segment is involved in group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Check out other big names from the same industry as NOTA.